Monopar secures an exclusive license from AstraZeneca's Alexion for ALXN-1840, aiming to advance treatment for Wilson's ...

Monopar Therapeutics is recovering a drug from the scrap heap of AstraZeneca’s rare disease pipeline. | Monopar Therapeutics ...

The company has made it easier to test for different protein modifications which are critical to the treatment of autoimmune ...

Monopar Therapeutics shares rose after the biotechnology company agreed to license a treatment for patients with a rare genetic condition from AstraZeneca unit Alexion. Shares of the Wilmette, Ill., ...

AstraZeneca has rolled out a fresh TV spot for its blockbuster-to-be Breztri, hitting the me | AstraZeneca has rolled out a ...

Sino-America clinical-stage biotech Eccogene announced that it will receive a $60 million payment from AstraZeneca, which is ...

Monopar Therapeutics' market value nearly tripled Thursday after the biotechnology company agreed to license a treatment for patients with a rare genetic condition from AstraZeneca unit Alexion.

AstraZeneca, a global biopharmaceutical company that develops and commercializes prescription medicines, became a household ...

Monopar Therapeutics (MNPR) announced that it has entered into an agreement with Alexion, AstraZeneca (AZN) Rare Disease for an exclusive ...

AstraZeneca AZN and Ionis Pharmaceuticals IONS announced that the Committee for Medicinal Products for Human Use (CHMP) has ...

Under the terms of the license agreement, Monopar will pay Alexion an upfront in the form of a cash payment and equity in Monopar. Future payments are based on tiered royalties on net sales and ...

AstraZeneca and Ionis are collaborating on the commercialisation of the drug following a December 2021 global agreement.